250 related articles for article (PubMed ID: 26836708)
1. A new PAMPA model using an in-house brain lipid extract for screening the blood-brain barrier permeability of drug candidates.
Bicker J; Alves G; Fortuna A; Soares-da-Silva P; Falcão A
Int J Pharm; 2016 Mar; 501(1-2):102-11. PubMed ID: 26836708
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of various PAMPA models to identify the most discriminating method for the prediction of BBB permeability.
Mensch J; Melis A; Mackie C; Verreck G; Brewster ME; Augustijns P
Eur J Pharm Biopharm; 2010 Mar; 74(3):495-502. PubMed ID: 20067834
[TBL] [Abstract][Full Text] [Related]
3. In vitro porcine blood-brain barrier model for permeability studies: pCEL-X software pKa(FLUX) method for aqueous boundary layer correction and detailed data analysis.
Yusof SR; Avdeef A; Abbott NJ
Eur J Pharm Sci; 2014 Dec; 65():98-111. PubMed ID: 25239510
[TBL] [Abstract][Full Text] [Related]
4. Prediction of blood-brain barrier permeation of α-adrenergic and imidazoline receptor ligands using PAMPA technique and quantitative-structure permeability relationship analysis.
Vucicevic J; Nikolic K; Dobričić V; Agbaba D
Eur J Pharm Sci; 2015 Feb; 68():94-105. PubMed ID: 25542610
[TBL] [Abstract][Full Text] [Related]
5. Blood-brain barrier models and their relevance for a successful development of CNS drug delivery systems: a review.
Bicker J; Alves G; Fortuna A; Falcão A
Eur J Pharm Biopharm; 2014 Aug; 87(3):409-32. PubMed ID: 24686194
[TBL] [Abstract][Full Text] [Related]
6. Physicochemical selectivity of the BBB microenvironment governing passive diffusion--matching with a porcine brain lipid extract artificial membrane permeability model.
Tsinman O; Tsinman K; Sun N; Avdeef A
Pharm Res; 2011 Feb; 28(2):337-63. PubMed ID: 20945153
[TBL] [Abstract][Full Text] [Related]
7. Application of PAMPA-models to predict BBB permeability including efflux ratio, plasma protein binding and physicochemical parameters.
Mensch J; Jaroskova L; Sanderson W; Melis A; Mackie C; Verreck G; Brewster ME; Augustijns P
Int J Pharm; 2010 Aug; 395(1-2):182-97. PubMed ID: 20635475
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of in vitro brain penetration: optimized PAMPA and MDCKII-MDR1 assay comparison.
Carrara S; Reali V; Misiano P; Dondio G; Bigogno C
Int J Pharm; 2007 Dec; 345(1-2):125-33. PubMed ID: 17624703
[TBL] [Abstract][Full Text] [Related]
9. Immobilized Artificial Membrane HPLC Derived Parameters vs PAMPA-BBB Data in Estimating in Situ Measured Blood-Brain Barrier Permeation of Drugs.
Grumetto L; Russo G; Barbato F
Mol Pharm; 2016 Aug; 13(8):2808-16. PubMed ID: 27377191
[TBL] [Abstract][Full Text] [Related]
10. Nasal-PAMPA: A novel non-cell-based high throughput screening assay for prediction of nasal drug permeability.
Henriques P; Bicker J; Silva S; Doktorovová S; Fortuna A
Int J Pharm; 2023 Aug; 643():123252. PubMed ID: 37479103
[TBL] [Abstract][Full Text] [Related]
11. High throughput artificial membrane permeability assay for blood-brain barrier.
Di L; Kerns EH; Fan K; McConnell OJ; Carter GT
Eur J Med Chem; 2003 Mar; 38(3):223-32. PubMed ID: 12667689
[TBL] [Abstract][Full Text] [Related]
12. Comparison of blood-brain barrier permeability assays: in situ brain perfusion, MDR1-MDCKII and PAMPA-BBB.
Di L; Kerns EH; Bezar IF; Petusky SL; Huang Y
J Pharm Sci; 2009 Jun; 98(6):1980-91. PubMed ID: 18837012
[TBL] [Abstract][Full Text] [Related]
13. Tuning the predictive capacity of the PAMPA-BBB model.
Müller J; Esső K; Dargó G; Könczöl Á; Balogh GT
Eur J Pharm Sci; 2015 Nov; 79():53-60. PubMed ID: 26344358
[TBL] [Abstract][Full Text] [Related]
14. Application of in vitro PAMPA technique and in silico computational methods for blood-brain barrier permeability prediction of novel CNS drug candidates.
Radan M; Djikic T; Obradovic D; Nikolic K
Eur J Pharm Sci; 2022 Jan; 168():106056. PubMed ID: 34740787
[TBL] [Abstract][Full Text] [Related]
15. pH-gradient PAMPA-based in vitro model assay for drug-induced phospholipidosis in early stage of drug discovery.
Balogh GT; Müller J; Könczöl A
Eur J Pharm Sci; 2013 Apr; 49(1):81-9. PubMed ID: 23439241
[TBL] [Abstract][Full Text] [Related]
16. Mimicking brain tissue binding in an in vitro model of the blood-brain barrier illustrates differences between in vitro and in vivo methods for assessing the rate of brain penetration.
Heymans M; Sevin E; Gosselet F; Lundquist S; Culot M
Eur J Pharm Biopharm; 2018 Jun; 127():453-461. PubMed ID: 29602020
[TBL] [Abstract][Full Text] [Related]
17. QSAR study on permeability of hydrophobic compounds with artificial membranes.
Fujikawa M; Nakao K; Shimizu R; Akamatsu M
Bioorg Med Chem; 2007 Jun; 15(11):3756-67. PubMed ID: 17418579
[TBL] [Abstract][Full Text] [Related]
18. A liposomal fluorescence assay to study permeation kinetics of drug-like weak bases across the lipid bilayer.
Eyer K; Paech F; Schuler F; Kuhn P; Kissner R; Belli S; Dittrich PS; Krämer SD
J Control Release; 2014 Jan; 173():102-9. PubMed ID: 24211703
[TBL] [Abstract][Full Text] [Related]
19. Development and validation of PAMPA-BBB QSAR model to predict brain penetration potential of novel drug candidates.
Kato R; Zeng W; Siramshetty VB; Williams J; Kabir M; Hagen N; Padilha EC; Wang AQ; Mathé EA; Xu X; Shah P
Front Pharmacol; 2023; 14():1291246. PubMed ID: 38108064
[TBL] [Abstract][Full Text] [Related]
20. Drug Permeability Profiling Using the Novel Permeapad® 96-Well Plate.
Jacobsen AC; Nielsen S; Brandl M; Bauer-Brandl A
Pharm Res; 2020 May; 37(6):93. PubMed ID: 32394114
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
